WuXi XDC and LCB Signed MOU for the Development and Manufacturing of Antibody-drug Conjugates

10 June 2021 | Thursday | News


WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, "LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in development and manufacturing of antibody-drug conjugates (ADCs).

Under the partnership, LCB will have access to XDC' integrated services in mAb, linker, payload, analytical and formulation development as well as ADC drug substance and drug product development and manufacturing. XDC will provide a full range of development and manufacturing services in one centralized region, which is within 2 hours' driving distance.

Dr. Yong-Zu Kim, CEO and President of LCB, commented, "We're excited to collaborate with WuXi XDC. This partnership will allow us to leverage XDC's world-class expertise in both innovative conjugation technologies and the comprehensive capabilities for the ADC development and manufacturing. We're looking forward to making more ADC products accessible to the patients."

"We're glad to partner with LegoChem Biosciences to proceed its leading ADC products into clinical development, eventually to the commercialization." Dr. Jimmy Li, CEO of WuXi XDC, commented, "With more ADC programs now advancing towards clinical trials and commercial production, we have witnessed increasing outsourced demand for ADCs in recent years. As one of a few CDMO companies who have the end-to-end capability and entire supply chain, we're committed to providing innovative technical solutions, reliable and sustainable manufacturing supply chain for global partners to benefit patients worldwide."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close